Revolutionizing Gene Therapy: UT Austin Scientists Pioneer a Multi-Mutation Editing Approach with Bacterial Origins
For decades, gene therapy has promised a cure for inherited diseases, but its potential has been hampered by limitations in precision, efficiency, and scalability. Now,a groundbreaking development from The University of Texas at Austin is poised to overcome these hurdles,offering a new era of hope for patients with complex genetic conditions. Researchers have unveiled a novel gene-editing technique leveraging naturally occurring bacterial defense mechanisms – called retrons - to together correct multiple disease-causing mutations within mammalian cells. This isn’t just an incremental advancement; it’s a paradigm shift in how we approach genetic disease.
The Challenge with Current Gene Editing & Why This Matters
existing gene-editing technologies, like CRISPR-Cas9, excel at targeting single, well-defined mutations.Though, many genetic diseases aren’t caused by a single error, but by a constellation of variations within a gene. Moreover, the sheer number of rare mutations – each affecting a small patient population – makes developing individualized therapies financially prohibitive. As Jesse Buffington, a graduate student at UT Austin and co-author of the study published in Nature Biotechnology, explains, “A lot of existing gene-editing methods are restricted to one or two mutations, which leaves a lot of people behind.” This leaves a meaningful portion of patients without viable treatment options.
The UT Austin team, led by Buffington and Professor Ilya Finkelstein, recognized this critical gap and sought a solution capable of addressing multiple mutations simultaneously. their answer lies in an unexpected source: bacteria.
Retrons: From Bacterial Defense to Human Therapy
Retrons are genetic elements found in bacteria that function as a defense system against viral infections. These elements create unique, single-stranded DNA structures that can be harnessed for gene editing. While retrons have been explored in mammalian cells previously, those attempts suffered from extremely low efficiency – correcting only around 1.5% of targeted cells.
The UT Austin team dramatically improved upon this, achieving a remarkable success rate of approximately 30% in inserting healthy DNA into target cells. this leap in efficiency is a game-changer, bringing retron-based gene editing closer to clinical viability. “We want to democratize gene therapy by creating off-the-shelf tools that can cure a large group of patients in one shot,” states finkelstein. “That should make it more financially viable to develop and much simpler from a regulatory standpoint as you only need one FDA approval.”
How the Retron System Works: A Powerful & Versatile Approach
The retron-based system operates by swapping out extended sections of defective DNA with healthy sequences. This “cut-and-paste” functionality allows a single retron “package” to address numerous mutations within a specific region of DNA, offering a significant advantage over technologies that target individual defects.
Crucially, the system utilizes RNA encapsulated within lipid nanoparticles for delivery. These nanoparticles are specifically engineered to overcome a major obstacle in gene therapy: efficient and safe delivery of the editing machinery into cells. This delivery method minimizes off-target effects and maximizes therapeutic impact.
Focusing on Cystic Fibrosis: A Real-World Application
The team is currently focusing its efforts on cystic fibrosis (CF), a life-threatening genetic disorder affecting the lungs and digestive system. Caused by mutations in the CFTR gene,CF leads to thick mucus buildup,chronic infections,and progressive lung damage.
Current CF therapies address only the most common mutations, leaving approximately 10% of patients without effective treatment options. Emily’s Entourage, a non-profit dedicated to CF research, has recognized the potential of this new technology and awarded a grant to support the UT Austin team’s work.
“Customary gene-editing technologies work best with single mutations and are expensive to optimize,” Buffington explains. “But there are over a thousand mutations that can cause CF. It’s not financially feasible for companies to develop a gene therapy for, say three people. With our retron-based approach, we can snip out a whole defective region and replace it with a healthy one, which can impact a much larger part of the CF population.”
Further bolstering this research, the Cystic Fibrosis Foundation has also provided a grant to target the region of the CFTR gene containing the most prevalent CF-causing mutations. The team is initially working with laboratory models mimicking CF symptoms and will eventually progress to testing in airway cells derived directly from patients.
Looking Ahead: A Future of Inclusive Gene Therapy
The research, conducted with support from Retronix Bio and the welch Foundation, represents a significant leap forward in gene therapy. The UT Austin team’s work, involving researchers Hung-Che Kuo, Kuang Hu
Keep reading